JP2020510668A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020510668A5 JP2020510668A5 JP2019547579A JP2019547579A JP2020510668A5 JP 2020510668 A5 JP2020510668 A5 JP 2020510668A5 JP 2019547579 A JP2019547579 A JP 2019547579A JP 2019547579 A JP2019547579 A JP 2019547579A JP 2020510668 A5 JP2020510668 A5 JP 2020510668A5
- Authority
- JP
- Japan
- Prior art keywords
- carbonitrile
- pyrrolo
- pyrazol
- pyrimidin
- fluorophenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- LSTMAJPRFFZYIT-UHFFFAOYSA-N 4-amino-7-[[1-(2-fluorophenyl)pyrazol-4-yl]methyl]-5-[2-(trifluoromethyl)pyrimidin-5-yl]pyrrolo[2,3-d]pyrimidine-6-carbonitrile Chemical compound NC=1C2=C(N=CN=1)N(C(=C2C=1C=NC(=NC=1)C(F)(F)F)C#N)CC=1C=NN(C=1)C1=C(C=CC=C1)F LSTMAJPRFFZYIT-UHFFFAOYSA-N 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021183048A JP7360434B2 (ja) | 2016-11-18 | 2021-11-10 | Ｃｆｔｒ増強物質としてのピロロピリミジン |
| JP2023169299A JP7592814B2 (ja) | 2016-11-18 | 2023-09-29 | Ｃｆｔｒ増強物質としてのピロロピリミジン |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662423919P | 2016-11-18 | 2016-11-18 | |
| US62/423,919 | 2016-11-18 | ||
| PCT/US2017/062148 WO2018094137A1 (en) | 2016-11-18 | 2017-11-17 | Pyrrolopyrimidines as cftr potentiators |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021183048A Division JP7360434B2 (ja) | 2016-11-18 | 2021-11-10 | Ｃｆｔｒ増強物質としてのピロロピリミジン |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020510668A JP2020510668A (ja) | 2020-04-09 |
| JP2020510668A5 true JP2020510668A5 (cg-RX-API-DMAC10.html) | 2020-12-17 |
| JP6978507B2 JP6978507B2 (ja) | 2021-12-08 |
Family
ID=62144793
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019547579A Active JP6978507B2 (ja) | 2016-11-18 | 2017-11-17 | Ｃｆｔｒ増強物質としてのピロロピリミジン |
| JP2021183048A Active JP7360434B2 (ja) | 2016-11-18 | 2021-11-10 | Ｃｆｔｒ増強物質としてのピロロピリミジン |
| JP2023169299A Active JP7592814B2 (ja) | 2016-11-18 | 2023-09-29 | Ｃｆｔｒ増強物質としてのピロロピリミジン |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021183048A Active JP7360434B2 (ja) | 2016-11-18 | 2021-11-10 | Ｃｆｔｒ増強物質としてのピロロピリミジン |
| JP2023169299A Active JP7592814B2 (ja) | 2016-11-18 | 2023-09-29 | Ｃｆｔｒ増強物質としてのピロロピリミジン |
Country Status (21)
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2013207252B2 (en) | 2012-01-06 | 2016-06-09 | H.Lundbeck A/S | Carbamate compounds and pharmaceutical compositions thereof |
| SMT202000540T1 (it) | 2014-10-06 | 2020-11-10 | Vertex Pharma | Modulatori di regolatore di conduttanza transmembrana di fibrosi cistica |
| EP3393465A1 (en) * | 2015-12-22 | 2018-10-31 | Proteostasis Therapeutics, Inc. | Methods of treating pulmonary diseases and disorders |
| JOP20190042B1 (ar) | 2016-09-30 | 2021-08-17 | Vertex Pharma | مُعدِّل لمنظم موصلية التليف الكيسي عبر الغشاء، وتركيبات صيدلانية، وطرق للعلاج، وعملية لتصنيع المُعدِّل |
| RU2757457C2 (ru) * | 2016-11-18 | 2021-10-18 | Систик Файбросис Фаундейшн | Пирролопиримидины в качестве потенциаторов мвтр |
| UY37513A (es) | 2016-12-09 | 2018-07-31 | Vertex Pharma | Modulador del regulador de conductancia transmembrana de fibrosis quística, composiciones farmacéuticas, métodos de tratamiento y proceso para producir el modulador |
| EP3554506B1 (en) | 2016-12-16 | 2021-04-28 | Cystic Fibrosis Foundation | Bycyclic heteroaryl derivatives as cftr potentiators |
| US11253509B2 (en) | 2017-06-08 | 2022-02-22 | Vertex Pharmaceuticals Incorporated | Methods of treatment for cystic fibrosis |
| BR112020000941A2 (pt) | 2017-07-17 | 2020-07-21 | Vertex Pharmaceuticals Incorporated | métodos de tratamento para fibrose cística |
| AU2018309043B2 (en) | 2017-08-02 | 2022-03-31 | Vertex Pharmaceuticals Incorporated | Processes for preparing pyrrolidine compounds |
| CA3078893A1 (en) | 2017-10-19 | 2019-04-25 | Vertex Pharmaceuticals Incorporated | Crystalline forms and compositions of cftr modulators |
| US11465985B2 (en) | 2017-12-08 | 2022-10-11 | Vertex Pharmaceuticals Incorporated | Processes for making modulators of cystic fibrosis transmembrane conductance regulator |
| TWI810243B (zh) | 2018-02-05 | 2023-08-01 | 美商維泰克斯製藥公司 | 用於治療囊腫纖化症之醫藥組合物 |
| DK3752510T3 (da) | 2018-02-15 | 2023-01-16 | Vertex Pharma | Makrocyklusser som modulatorer af cystisk fibrose transmembrankonduktansregulator, farmaceutiske sammensætninger deraf, deres anvendelse i behandlingen af cystisk fibrose og fremgangsmåde til fremstilling deraf |
| EP3774825A1 (en) | 2018-04-13 | 2021-02-17 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator |
| TWI848092B (zh) | 2019-04-03 | 2024-07-11 | 美商維泰克斯製藥公司 | 囊腫纖維化跨膜傳導調節蛋白調節劑 |
| MX2021015133A (es) * | 2019-06-10 | 2022-01-24 | Novartis Ag | Derivado de piridina y pirazina para el tratamiento de la fibrosis quistica, enfermedad pulmonar obstructiva cronica y bronquiectasia. |
| JP2022541178A (ja) | 2019-07-15 | 2022-09-22 | ノバルティス アーゲー | （ｓ）－３－アミノ－６－メトキシ－ｎ－（３，３，３－トリフルオロ－２－ヒドロキシ－２－メチルプロピル）－５－（トリフルオロメチル）ピコリンアミド製剤 |
| TWI899097B (zh) | 2019-08-14 | 2025-10-01 | 美商維泰克斯製藥公司 | 製備cftr調節劑之方法 |
| EP4013760A1 (en) | 2019-08-14 | 2022-06-22 | Vertex Pharmaceuticals Incorporated | Crystalline forms of cftr modulators |
| TWI867024B (zh) | 2019-08-14 | 2024-12-21 | 美商維泰克斯製藥公司 | 囊腫纖維化跨膜傳導調節蛋白之調節劑 |
| CN111138439B (zh) * | 2020-01-17 | 2021-06-25 | 厦门大学 | 氟代吡咯并嘧啶类化合物及其制备方法和应用 |
| WO2021176049A1 (en) | 2020-03-06 | 2021-09-10 | Bayer Aktiengesellschaft | Pyrazolopyrazines acting on cancers via inhibition of cdk12 |
| CN116033895A (zh) | 2020-08-20 | 2023-04-28 | 小利兰·斯坦福大学托管委员会 | 用于治疗以黏液分泌过多为特征的呼吸系统疾病的方法 |
| AU2021397294A1 (en) | 2020-12-10 | 2023-07-06 | Vertex Pharmaceuticals Incorporated | Methods of treatment for cystic fibrosis |
| WO2024096629A1 (ko) * | 2022-11-02 | 2024-05-10 | 일동제약 주식회사 | Cftr 조절제 화합물을 포함하는 점안용 조성물 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK0674641T3 (da) * | 1992-12-17 | 1999-09-27 | Pfizer | Pyrrolopyrimidiner som CRF-antagonister |
| IL149462A0 (en) | 2001-05-09 | 2002-11-10 | Warner Lambert Co | Method of treating or inhibiting neutrophil chemotaxis by administering a mek inhibitor |
| EP1412327A2 (en) | 2001-05-30 | 2004-04-28 | LG Biomedical Institute | Inhibitors of protein kinase for the treatment of disease |
| WO2004100868A2 (en) * | 2003-04-23 | 2004-11-25 | Abbott Laboratories | Method of treating transplant rejection |
| WO2005074603A2 (en) * | 2004-02-03 | 2005-08-18 | Abbott Laboratories | Aminobenzoxazoles as therapeutic agents |
| CN101389630A (zh) * | 2005-12-29 | 2009-03-18 | 艾博特公司 | 蛋白激酶抑制剂 |
| KR20090007319A (ko) * | 2006-03-11 | 2009-01-16 | 베르날리스 (알 앤드 디) 리미티드 | Ｈｓｐ90 억제제로서 사용되는 피롤로피리미딘 유도체 |
| KR20130087054A (ko) * | 2006-04-04 | 2013-08-05 | 더 리젠트스 오브 더 유니이버시티 오브 캘리포니아 | 키나제 길항물질 |
| EP2217239A2 (en) * | 2007-11-07 | 2010-08-18 | Foldrx Pharmaceuticals, Inc. | Modulation of protein trafficking |
| HRP20150947T1 (hr) | 2009-01-08 | 2015-10-09 | Curis, Inc. | Inhibitori fosfoinositid 3-kinaze sa skupinom koja veže cink |
| WO2013071232A1 (en) | 2011-11-11 | 2013-05-16 | Beta Cat Pharmaceuticals, Llc | Compositions and methods for inhibition of tbl-1 binding to disease-associated molecules |
| US8828998B2 (en) * | 2012-06-25 | 2014-09-09 | Infinity Pharmaceuticals, Inc. | Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors |
| WO2014060431A1 (en) * | 2012-10-16 | 2014-04-24 | Almirall, S.A. | Pyrrolotriazinone derivatives as pi3k inhibitors |
| WO2015091532A1 (en) * | 2013-12-19 | 2015-06-25 | Almirall, S.A. | Pyrrolopyrimidine derivatives as pi3k inhibitors |
| RU2757457C2 (ru) | 2016-11-18 | 2021-10-18 | Систик Файбросис Фаундейшн | Пирролопиримидины в качестве потенциаторов мвтр |
-
2017
- 2017-11-17 RU RU2019118623A patent/RU2757457C2/ru active
- 2017-11-17 US US15/815,809 patent/US10301315B2/en active Active
- 2017-11-17 ES ES17872726T patent/ES2983686T3/es active Active
- 2017-11-17 WO PCT/US2017/062148 patent/WO2018094137A1/en not_active Ceased
- 2017-11-17 JP JP2019547579A patent/JP6978507B2/ja active Active
- 2017-11-17 MX MX2021012639A patent/MX2021012639A/es unknown
- 2017-11-17 IL IL296279A patent/IL296279A/en unknown
- 2017-11-17 CN CN202211239693.0A patent/CN115850268B/zh active Active
- 2017-11-17 KR KR1020237033420A patent/KR102824092B1/ko active Active
- 2017-11-17 AU AU2017362350A patent/AU2017362350B2/en active Active
- 2017-11-17 EP EP24170395.8A patent/EP4424311A3/en active Pending
- 2017-11-17 PE PE2019001045A patent/PE20200739A1/es unknown
- 2017-11-17 MX MX2019005822A patent/MX387203B/es unknown
- 2017-11-17 CN CN201780083801.0A patent/CN110337294B/zh active Active
- 2017-11-17 CR CR20190292A patent/CR20190292A/es unknown
- 2017-11-17 PL PL17872726.9T patent/PL3541390T3/pl unknown
- 2017-11-17 SG SG10202106949XA patent/SG10202106949XA/en unknown
- 2017-11-17 EP EP17872726.9A patent/EP3541390B1/en active Active
- 2017-11-17 RU RU2021129721A patent/RU2021129721A/ru unknown
- 2017-11-17 KR KR1020197017510A patent/KR102585398B1/ko active Active
- 2017-11-17 UA UAA201906838A patent/UA125400C2/uk unknown
-
2019
- 2019-04-05 US US16/377,005 patent/US10494374B2/en active Active
- 2019-05-15 IL IL266668A patent/IL266668B2/en unknown
- 2019-05-16 CL CL2019001334A patent/CL2019001334A1/es unknown
- 2019-05-16 PH PH12019501098A patent/PH12019501098A1/en unknown
- 2019-05-17 DO DO2019000126A patent/DOP2019000126A/es unknown
- 2019-06-07 CO CONC2019/0005993A patent/CO2019005993A2/es unknown
- 2019-06-17 EC ECSENADI201943120A patent/ECSP19043120A/es unknown
- 2019-09-20 US US16/578,277 patent/US20200017512A1/en not_active Abandoned
-
2021
- 2021-02-18 US US17/179,062 patent/US20210171534A1/en not_active Abandoned
- 2021-11-10 JP JP2021183048A patent/JP7360434B2/ja active Active
-
2022
- 2022-03-16 AU AU2022201816A patent/AU2022201816B2/en active Active
-
2023
- 2023-04-13 US US18/134,455 patent/US20230250100A1/en active Pending
- 2023-09-29 JP JP2023169299A patent/JP7592814B2/ja active Active
-
2024
- 2024-07-18 IL IL314404A patent/IL314404B2/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020510668A5 (cg-RX-API-DMAC10.html) | ||
| USD821188S1 (en) | Towel clip | |
| USD809988S1 (en) | Leveling block | |
| USD809987S1 (en) | Leveling block | |
| USD728654S1 (en) | Network camera | |
| USD739509S1 (en) | L-type pipe fitting | |
| RU2021102805A (ru) | 4,6-ЗАМЕЩЕННЫЕ ПИРАЗОЛО[1,5-a]ПИРАЗИНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ ЯНУС-КИНАЗЫ | |
| CN110139865A (zh) | Fgfr抑制剂 | |
| JP2013173781A5 (cg-RX-API-DMAC10.html) | ||
| USD755903S1 (en) | Building block | |
| USD784709S1 (en) | Interlocking block for artwork | |
| CN111683928A (zh) | 作为fgfr抑制剂的吡嗪-2(1h)-酮类化合物 | |
| USD818056S1 (en) | Building block | |
| JP2017520613A5 (cg-RX-API-DMAC10.html) | ||
| CA2902403C (en) | Pde3/pde4 inhibitor/muscarinic receptor antagonist combination | |
| LT3986561T (lt) | Pirido[2,3-d]pirimidino dariniai kaip žmogaus imunodeficito viruso replikacijos inhibitoriai | |
| USD859668S1 (en) | Back roll spinal brace support | |
| USD754551S1 (en) | Locating and tracking tool | |
| MX2016001639A (es) | Formas de dosificacion de liberacion prolongada para un inhibidor de jak 1 (cinasa de janus 1). | |
| USD755904S1 (en) | Building block | |
| USD754260S1 (en) | Building block | |
| CN109790159A (zh) | 抗流感病毒嘧啶衍生物 | |
| MX2022013274A (es) | Compuestos de triazolo-pirimidina fusionados que tienen aplicacion farmaceutica util. | |
| HK1254343A1 (zh) | 药物制剂 | |
| WO2016205738A3 (en) | Delivery systems for controlled drug release |